Responses
Rheumatoid arthritis
Original article
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
Compose a Response to This Article
Other responses
No responses have been published for this article.